KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $76.2 million.

  • Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.77% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 1.77%. This contributed to the annual value of $76.2 million for FY2024, which is 16.52% up from last year.
  • As of FY2024, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $76.2 million, which was up 16.52% from $65.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $76.2 million for FY2024, and its period low was $35.0 million during FY2020.
  • In the last 3 years, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $65.4 million in 2023 and averaged $68.1 million.
  • Data for Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 47.37% (in 2021) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $35.0 million in 2020, then skyrocketed by 47.37% to $51.6 million in 2021, then grew by 21.23% to $62.5 million in 2022, then rose by 4.61% to $65.4 million in 2023, then grew by 16.52% to $76.2 million in 2024.